SCHEMBL6378124

SCHEMBL6378124

N#Cc1ccccc1-c1ccc[c]c1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.40
AR P10275 7/20 0.40
ESR2 Q92731 1/20 0.39
PDK2 Q15119 1/20 0.38
PGR P06401 2/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
GABRA1 P14867 3/20 0.36
GABRG2 P18507 3/20 0.36
GABRB3 P28472 3/20 0.36
GABRA3 P34903 3/20 0.36
GABRA5 P31644 2/20 0.36
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TSHR P16473 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
GABRA2 P47869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290700 0.84 CYP1A2 (0.35) PTPN5ARPDK2PGRCYP1A2
SCHEMBL6987649 0.75 HSD11B1 (0.41) ARCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL2431241 0.75 HTR1A (0.33) PDK2GPBAR1
SCHEMBL8114100 0.74 ESR2 (0.46) PTPN5ARESR2GABRG2GABRB3
SCHEMBL11032497 0.74 ALDH1A1 (0.38) PDK2
SCHEMBL3583635 0.74 CYP2A6 (0.38) ARPDK2GPBAR1TSHR
SCHEMBL7015180 0.74 ESR2 (0.42) PTPN5ESR2PDK2GABRG2GABRB3
SCHEMBL6334156 0.74 AR (0.36) ARPDK2GPBAR1
SCHEMBL1206349 0.73 ESR2 (0.44) PTPN5ARESR2PDK2GABRG2
SCHEMBL8251795 0.73 AR (0.62) PTPN5ARESR2PDK2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050267044-A1 Novel compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267044-A1 Novel compounds and compositions as cathepsin S inhibitors CTSS, CTSB, CTSE PTPN5 3012/4885AR 3904/4885ESR2 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.